Poolbeg Pharma has been granted a patent in South Africa for its lead drug candidate, POLB 001, which targets severe influenza and cytokine storms linked to cancer immunotherapy side effects. The patent, valid until December 2038, strengthens the company's intellectual property portfolio and enhances the drug's commercial appeal. POLB 001 is a p38 MAP kinase inhibitor designed to prevent excessive immune responses, including cytokine release syndrome. Poolbeg is focused on expanding its patent coverage globally to attract potential partners and increase the drug's value.
In the first half of 2026, Toobit enhanced its trading platform by integrating AI-powered tools like Synapse and AI Agent Trade Kit, expanding tokenized TradFi futures with over 100 pairs, and offering zero-fee spot trading. The exchange also improve...
BlackRock Inc. has crossed the 3% threshold for direct voting rights in Syensqo SA, holding 3.07% voting rights and 0.97% equivalent financial instruments as of June 19, 2026. This move, disclosed under Belgian transparency laws, indicates BlackRock'...
Mowi ASA has agreed to sell its Canada East salmon farming operations, totaling 9,000 GWT, to Cooke Inc. for CAD 225 million. This divestment aims to streamline Mowi's farming portfolio and concentrate on its main farming areas. The sale is expected ...
Sigenergy has started construction on Phase II of its Nantong Intelligent Energy Center and a new joint venture production facility with Xianghua Hardware Technology. This expansion will increase its manufacturing base to nearly 400,000 square meters...
Paris Saint-Germain has declared Bradley Barcola, their 23-year-old star forward, untouchable despite interest from Arsenal and Liverpool. PSG originally bought Barcola for €45 million and now values him at €100-120 million, with a contract until 202...
